Navigation Links
Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting
Date:4/16/2008

BELLEVUE, WA, April 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that data from pharmacokinetic studies of PX-12 and preclinical studies of PX-866 were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, held April 12-16, 2008. Information from the studies may guide future clinical development plans for these product candidates. Oncothyreon is currently conducting a Phase 2 trial of PX-12 in patients with advanced pancreatic cancer and PX-866 is expected to enter a Phase 1 trial in patients with advanced cancers in the second quarter of 2008.

PX-12

PX-12 is an irreversible inhibitor of thioredoxin (Trx)-1, a protein that is over-expressed in many tumor types and is associated with aggressive tumor growth and poor prognoses. In a previous Phase 1 study, PX-12 treatment lowered circulating levels of Trx-1 in patients and a Trx-1 decrease of 25% or greater was associated with increased survival.

The current study examined Trx-1 levels in the serum of patients receiving PX-12 in two ongoing clinical trials and in healthy volunteers, and the data were reported in a poster session yesterday (Abstract # 4453). Key findings of the study are:

- PX-12 reduced plasma Trx-1 levels in all patients with initial levels

greater than 18 ng/mL, the upper limit of the normal range. Patients

with normal Trx-1 levels remained in the normal range following PX-12

treatment.

- Thirty-three percent of patients with elevated Trx-1 levels achieved

stable disease with PX-12 treatment. No patients achieved stable

disease if their starting Trx-1 levels were within the normal range.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
(Date:9/19/2014)... 2014 Cereal grain scientists, quality ... gather October 5–8, 2014, for the AACC International ... Center in Providence, Rhode Island. The comprehensive scientific ... food scientists, chemists, microbiologists, nutritionists, and those interested ... management. To date, 1,000 attendees have registered for ...
(Date:9/18/2014)... USA (PRWEB) September 18, 2014 Bipartisan ... of a bill designed to stimulate development and commercialization ... is being praised by leaders of SPIE, the ... the Revitalizing American Manufacturing and Innovation (RAMI) Act, now ... bill’s authors have said they are optimistic that it ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3
... ... EDMONTON, May 9 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS),a ... update on its pipeline products, HYC750 and development with,BioCyDex Inc., ... Bio. Inc. for HYC750, a technology based on hyaluronic acid that,has ...
... May 9 The Alexander von Humboldt,Foundation, one of ... has named Dr. Robert Knight as a winner of ... area of neurobiology.,It is the only prize that the ... Germany, the Humboldt Foundation reviews a,select group of international ...
... 9 ATS Medical, Inc. (Nasdaq:,ATSI), manufacturer and ... it will participate at the Rodman & Renshaw,5th ... Beach Plaza,Hotel in Monte Carlo on Tuesday, May ... Medical, will present at 9:20 a.m. local time., ...
Cached Biology Technology:BioMS Medical Provides Update On Pipeline Products 2BioMS Medical Provides Update On Pipeline Products 3NeuroFocus Chief Science Advisor Wins Humboldt Prize 2ATS Medical to Participate at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:9/18/2014)... ANTONIO, September 18, 2014 New research into the ... causes a severe hemorrhagic disease in humans similar to ... essential for CCHFV infection. This discovery has the potential ... the pathogen. , The research, reported in ... Pathogens and conducted by scientists at the Texas ...
(Date:9/18/2014)... prompts millions of Americans to undertake jaunts into the countryside ... little longer within a century, according to new research. , ... of the United States as summer temperatures linger later into ... Global Ecology and Biogeography . For instance, the paper birch ... of New Hampshire could change color one to three ...
(Date:9/18/2014)... across racial and ethnic groups describe losing eyesight ... day-to-day life, more so than other conditions including: ... of African-Americans, 49% of non-Hispanic whites, 43% of ... disease or ailment is the worst that could ... followed by AIDS/HIV. Hispanics and Asians ranked ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... has won a $1.175 million grant that will support its ... Geurts, who has spent his career looking for clues to ... contents of gold, lead and other heavy atoms, said the ... constructing and commissioning a highly complex detector system to using ...
... that sheds new light on the causes of Parkinson,s disease, ... energy-producing machinery, the mitochondria. A shutdown in fuel can have ... of the body,s energy despite making up only 2 percent ... the mitochondria with FDA approved drugs early on may prevent ...
... billion last year in health research from all public ... That amount represents only 5.6% of the $2.47 trillion ... health dollarwhich varies no more than 0.2% from 2005 ... http://www.researchamerica.org/uploads/healthdollar09.pdf . The 2009 investment grew by ...
Cached Biology News:Grant advances quark-gluon plasma studies
 2Grant advances quark-gluon plasma studies
 3In Parkinson's disease, brain cells abandon mitochondria, researchers report 2In Parkinson's disease, brain cells abandon mitochondria, researchers report 3US invested $139 billion in health research in 2009 2
Roll of Mesh 5m x 25cm...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
... (PPase-2A) is a serine/threonine phosphatase isolated from ... as the heterodimer of 60kDa (A) and ... to dephosphorylate the a-subunit of phosphorylase kinase. ... broad substrate specificity and may play a ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Biology Products: